MIGENIX Reports Effectiveness of MX-2401 in Pneumonia Model

27-Jun-2005

MIGENIX Inc., a clinical-stage developer of drugs for infectious and degenerative diseases, has obtained positive results on the effectiveness of its lipopeptide anti-bacterial product candidate, MX-2401, in accepted experimental models of pneumonia and soft tissue infections. This injectable compound is in preclinical development for the treatment of serious gram- positive infections. The company recently received a $9.3 million investment commitment from the Government of Canada's Technology Partnerships Canada program towards the development of MX-2401

In studies conducted by Dr. William Craig at the University of Wisconsin Medical School and the VA Medical Center, the ability of MX-2401 to kill Streptococcus pneumoniae in the lungs and/or thighs of infected mice (a model used widely to predict efficacy in human pneumonia and complicated skin and soft tissue infections) and the efficacy of MX-2401 against another serious gram-positive pathogen, Staphylococcus aureus were confirmed. Dr. Craig is an internationally recognized expert in anti-infective therapy and Head of Clinical Pharmacology at the University of Wisconsin Medical School and a member of the MIGENIX Clinical Advisory Board.

Other news from the department research and development

Most read news

More news from our other portals

So close that even
molecules turn red...